Literature DB >> 1379125

Haemodynamic sequelae of pulmonary fibrosis following intratracheal bleomycin in rats.

J H Williams1, P Bodell, S Hosseini, H Tran, K M Baldwin.   

Abstract

OBJECTIVE: Intratracheal instillation of bleomycin in rats has been extensively used as an animal model of pulmonary fibrosis in humans, although it produces a patchy, airway based response. We proposed that the haemodynamic sequelae of the bleomycin model might be less severe than those associated with more diffuse lung injury.
METHODS: Pulmonary and systemic haemodynamic indices were examined in adult Sprague-Dawley rats (approximately 400 g, n = 10) both at rest and during submaximal exercise on a rodent treadmill, approximately 60 days after intratracheal bleomycin (6 units.kg-1), and the results compared to a control group (n = 6).
RESULTS: Compared to controls, mean pulmonary artery pressure (PPA) was increased by intratracheal bleomycin (p = 0.02) both at rest [24.5 (SEM 2.6) v 18.2(0.9) mm Hg] and during exercise [34.7(3.0) v 26.7(0.7) mm Hg]. PPA-pulse product was also increased, with a similar trend in right ventricular work index, but cardiac index was not altered. Right ventricular hypertrophy was noted on necropsy examination. Consistent with pulmonary fibrosis, lung dry weight, total protein, and hydroxyproline were also raised, and these values correlated strongly with (mean) PPA at rest (r2 = 0.86, 0.81, 0.69, respectively) and during exercise (r2 = 0.81, 0.79, 0.65, respectively). Packed cell volume was increased by intratracheal bleomycin, at 49(1) v 45(1)%, p = 0.02. CaO2 tended to decrease with exercise in the bleomycin group, although this was not statistically significant, while systemic oxygen delivery and consumption were not altered.
CONCLUSIONS: Pulmonary hypertension and right ventricular hypertrophy occur in this model of lung fibrosis, and correlate with the severity of fibrosis. However, these sequelae were less severe than those previously demonstrated in association with crotalaria ingestion. We suggest that the haemodynamic sequelae of the intratracheal bleomycin model are consistent with patchy, airway based fibrosis, but reflect less well the haemodynamic sequelae of more diffuse fibrotic injury associated with systemic processes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1379125     DOI: 10.1093/cvr/26.4.401

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  5 in total

Review 1.  Pathogenic mechanisms of pulmonary arterial hypertension.

Authors:  Stephen Y Chan; Joseph Loscalzo
Journal:  J Mol Cell Cardiol       Date:  2007-09-20       Impact factor: 5.000

2.  Cardiopulmonary and histological characterization of an acute rat lung injury model demonstrating safety of mesenchymal stromal cell infusion.

Authors:  Rudolf K Braun; Jill M Koch; Timothy A Hacker; David Pegelow; Jaehyup Kim; Amish N Raval; Eric G Schmuck; Denise J Schwahn; Derek J Hei; John M Centanni; Marlowe Eldridge; Peiman Hematti
Journal:  Cytotherapy       Date:  2016-04       Impact factor: 5.414

3.  Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension.

Authors:  Marc Iglarz; Kyle Landskroner; Yasmina Bauer; Magali Vercauteren; Markus Rey; Berengère Renault; Rolf Studer; Enrico Vezzali; Diego Freti; Hakim Hadana; Manuela Schläpfer; Christophe Cattaneo; Céline Bortolamiol; Edgar Weber; Brian R Whitby; Stéphane Delahaye; Daniel Wanner; Pauline Steiner; Oliver Nayler; Patrick Hess; Martine Clozel
Journal:  J Cardiovasc Pharmacol       Date:  2015-11       Impact factor: 3.105

4.  Impaired Myofilament Contraction Drives Right Ventricular Failure Secondary to Pressure Overload: Model Simulations, Experimental Validation, and Treatment Predictions.

Authors:  Jennifer L Philip; Ryan J Pewowaruk; Claire S Chen; Diana M Tabima; Daniel A Beard; Anthony J Baker; Naomi C Chesler
Journal:  Front Physiol       Date:  2018-06-27       Impact factor: 4.566

5.  GLP-1 receptor agonist ameliorates experimental lung fibrosis.

Authors:  Juan Fandiño; Laura Toba; Lucas C González-Matías; Yolanda Diz-Chaves; Federico Mallo
Journal:  Sci Rep       Date:  2020-10-22       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.